Johnson & Johnson has paused further enrollment in a phase 2b trial of its AC Immune-partnered Alzheimer’s disease ca...
Johnson & Johnson paused enrollment in a Phase 2b trial of an AC Immune-partnered Alzheimer's candidate amid reported recruitment challenges.
Why it mattersPhase 2b pause for the Alzheimer's candidate signals trial recruitment risks, prompting CRO and resource reallocation.